Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) dropped 0.6% during trading on Thursday . The company traded as low as $52.12 and last traded at $52.92. Approximately 75,425 shares changed hands during trading, an increase of 51% from the average daily volume of 50,104 shares. The stock had previously closed at $53.26.
Neoleukin Therapeutics Stock Performance
The company’s 50-day moving average is $40.68 and its 200-day moving average is $37.95. The firm has a market cap of $511.25 million, a price-to-earnings ratio of -17.02 and a beta of 1.11.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Featured Stories
- Five stocks we like better than Neoleukin Therapeutics
- How Technical Indicators Can Help You Find Oversold Stocks
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Most Volatile Stocks, What Investors Need to Know
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- What is a buyback in stocks? A comprehensive guide for investors
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
